<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043194</url>
  </required_header>
  <id_info>
    <org_study_id>wei liu</org_study_id>
    <nct_id>NCT05043194</nct_id>
  </id_info>
  <brief_title>Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis</brief_title>
  <acronym>UDACPPNAC</acronym>
  <official_title>The Preventive Study of Ursodeoxycholic Acid(UDCA) on Total Parenteral Nutrition Cholestasis(PNAC) in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to confirm whether the preventive use of ursodeoxycholic acid on the 5th day&#xD;
      after birth in preterm infants who started parenteral nutrition therapy can reduce the&#xD;
      occurrence of enteral nutrition-related cholestasis in preterm infants. This study examined&#xD;
      the safety and efficacy of ursodeoxycholic acid (UDCA) in preventing Cholestasis Associated&#xD;
      with Total Parenteral Nutrition in preterm infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators compared oral administration of UDCA prophylaxis with no prophylaxis in a&#xD;
      randomized, open-label, proof-of-concept trial in preterm neonates with PN therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>direct bilirubin value of participants</measure>
    <time_frame>up to 10 weeks</time_frame>
    <description>Weekly direct bilirubin values in μmol/L for preterm infants during hospitalization will be collected to assess the severity of cholestasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The γ-GT activity level of participants</measure>
    <time_frame>up to 10 weeks</time_frame>
    <description>Weekly γ-GT values in U/L for preterm infants during hospitalization will be collected to assess the severity of cholestasis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cholestasis of Parenteral Nutrition</condition>
  <arm_group>
    <arm_group_label>ursodeoxycholic acid arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premature infants who meet the inclusion criteria take preventive oral ursodeoxycholic acid on the 7th day after birth. ursodeoxycholic acid capsules (Ursofalk, 250 mg/capsules), starting with oral administration of pharmacologic doses of 20-25mg/kg/d, twice daily, until they were discharged .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the control arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The control group was treated with UDCA after the occurrence of cholestasis.ursodeoxycholic acid capsules (Ursofalk, 250 mg/capsules), starting with oral administration of pharmacologic doses of 20-25mg/kg/d, twice daily, until they were discharged .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid 250 Mg Oral Capsule</intervention_name>
    <description>prevention</description>
    <arm_group_label>the control arm</arm_group_label>
    <arm_group_label>ursodeoxycholic acid arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. admission to the hospital within 24 hours after birth&#xD;
&#xD;
          2. gestational ages:28-32 weeks&#xD;
&#xD;
          3. requiring TPN during the first days of life&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. major congenital abnormalities, chromosomal abnormality congenital intrauterine&#xD;
             infection, genetic metabolic diseases structural liver abnormality&#xD;
&#xD;
          2. surgical treatment was taken during hospitalization&#xD;
&#xD;
          3. with severe symptoms of digestive system disease before TPN&#xD;
&#xD;
          4. incompletion or withdrawal of treatment during hospitalization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>liwen chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wei Liu</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wei liu, doctor</last_name>
      <phone>027-83663332</phone>
      <email>liuweistudy@126.com</email>
    </contact>
    <contact_backup>
      <last_name>siying liu, master</last_name>
      <phone>027-83663332</phone>
      <email>liusiying5200527@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Wei Liu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

